Recent Financings Of Private Companies, October 2013
• By Deanna Kamienski, Beth Allan, Andrea Mancini, Amanda Micklus, Maureen Riordan, and Theresa Surprenant
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Device, and Pharmaceuticals sector. This month’s column covers deals announced August through September 2013.
Carmenta Bioscience brings in $2mm through its seed round
Carmenta Bioscience Inc. (prenatal tests) raised $2mm through its seed round. Company management, Life Science Angels, and individual scientists...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.
As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.
Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.
The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.
Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.